Welcome to the Cellebrite's First Quarter 2023 Financial Results Conference Call. At this time, all participants have been placed on a listen-only mode. And the floor will be open for your questions following the presentation. [Operator Instructions] I would now like to turn the call over to your first speaker today Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Thank you, Shelby. Good morning, everybody. Cellebrite's first quarter 2023 financial results conference call. Joining me today are Yossi Carmil, Cellebrite's CEO; and Dana Gerner Cellebrite's CFO. There is a slide presentation that accompanies our prepared remarks and you can advance the slides in the webcast viewer to follow our commentary. We will be sure to call out the slide number we were referring to in our remarks. This call is being recorded and a replay of the recording will be made available on our website shortly after the call. Let's start with slide number 2. A copy of today's press release and financial statements including the GAAP to non-GAAP reconciliations the slide presentation all of that is available on the company's Investor Relations website at investors.cellebrite.com. Please note that the quarterly financial tables and supplemental data for the first quarter and each quarter for the past two years will be posted to our Investor Relations website after this call concludes. Also unless stated otherwise, our first quarter 2023 financial metrics as well as the financial metrics provided in our outlook that will be discussed on today's conference call will be on a non-GAAP basis only all historical comparisons over the first quarter of 2022 unless otherwise noted. In addition, please note that the statements made during this call that are not statements of historical facts constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. They could also cause the actual results to differ materially from historical results and/or from forecasts. Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company's annual report on Form 20-F filed with the SEC on April 27, 2023. The company does not take -- undertake to update any forward-looking statements to reflect future events or circumstances. Slide number 3 provides the agenda for today's call. As you will hear, we are pleased with our Q1 financial performance and strategic progress and we are focused on delivering on our full year 2023 targets. And with that said I'll now turn the call over to Yossi Carmil, Cellebrite's CEO.

Thank you, Andy and thank you all for joining us today. As reflected on slide 5 Cellebrite's first quarter results and KPIs demonstrate a strong start to 2023. The first quarter of 2023 was also marked by Cellebrite continued progress with key strategic initiatives, aimed at advancing innovation and expanding our customers' relationship. It is really rewarding to see customers increasingly turn to Cellebrite for powerful digital intelligence software solutions that will help them modernize their investigative workflow. This is translating into higher usage for our Collect and Review solutions and increasing traction for additional growth engines like our Investigative Analytics and our Case and Evidence Management offerings all of which is helping grow wallet share within our installed customer base and capture new logos. As a result, we move forward with a solid momentum in a healthy marketplace. Before I share some observations about our market positioning, highlights from the quarter, the market environment and our outlook for the remainder of 2023, I will briefly review our first quarter results and other select metrics. The Q1 revenue of $71.2 million grew 14% over the prior year with subscription software revenue growing 27%. Our ARR grew 30% to $261 million. We delivered another quarter with dollar-based NRR greater than 120%. We closed 21 large deals each valued at greater than US$0.5 million. We reported Q1 adjusted EBITDA of $7.3 million for a margin of 10% and non-GAAP EPS of $0.03. And we generated more than $12 million in cash from operations and ended Q1 with cash and investments totaling just over $221 million and no outstanding debt. Turning to slide 6. Cellebrite is recognized by public and private sector customers, industry experts and investors as a market leader in digital intelligence software solution. The cornerstone of our business continues to…

Thank you, Yossi. Let's begin a review on slide 11. Total revenue of $71.2 million for the first quarter was up 14%. This was driven primarily by 27% growth in subscription revenue. As detailed on this slide, 86% of our total quarterly revenue came from software subscriptions, up from 77% one year ago. Slide 12 details our ARR growth, which is an important forward-looking KPI for Cellebrite sales momentum and the trajectory of future revenue. As Yossi noted, ARR grew 30% year-on-year, reaching $261 million at the end of Q1, primarily as a result of continued expansion with existing customers. Within this category, we produced strong ARR growth for our Collect & Review solutions mainly due to further penetration of Premium into our installed base. This expansion is augmented by faster growth from our Pathfinder investigative analytics and Guardian case management solutions albeit on a much smaller basis. And I'd like to briefly elaborate on churn, which reflects the impact of license reductions and cancellations. Churn was 10% in the first quarter, up to approximately two percentage points of the churn is directly tied to erosion from customers in countries where we have discontinued new sales activities and are no longer pursuing license renewals. We anticipate that the impact from voluntary churn will likely remain at the current levels throughout 2023 and gradually lessen as we move into the latter part of 2024. Slide 13 details the historical trends for our non-GAAP gross margins and non-GAAP operating expenses, which exclude share-based compensation amortization of intangible assets and acquisition-related expenses. Our first quarter 2023 gross margin was 83.1%, which was up slightly from 82.8% in the same period one year ago. Our gross margin performance in Q1 reflects the positive impact from the sustained growth we have delivered in higher margin…

The floor is now open for questions. [Operator Instructions] We'll take our first question from Jonathan Ho with William Blair.

Hi, good morning, and congratulations on the strong results. Just wanted to I guess get a little bit more color on the decision to voluntarily stop selling in some regions. Could you maybe give us a sense of how large the customer base is in these areas? And maybe what changed to cause you to stop selling in these areas now?

Shall I take it Dana?

Please.

So first of all, I would say nothing changed in the base that all the elements of making sure that the technology, which is aimed to do good goes to the right places and being used in the right manner is part of our business for years by now. And obviously, human rights and data security and data privacy are important to us. Just to maybe refresh 2021, we formed on Ethics and Integrity Committee, which advised the Board regarding that policy. So that was basically something that even strengths our existing compliance and ethical practices within the company. So within that part, as we did over the last past years, where we stopped new sales activities in dozens of countries we decided to add additional countries. As part of that ongoing effort, I would say to first of all, make sure we have the right operation that we focus on the right areas where we can be sure that the way our products are being operated are in the right manner. And that means, Jonathan, basically we are getting -- we always been cautious about that. We are getting better with that. And within time based on our ongoing, ongoing ethics compliance we are upgrading our activity in that respect blocking or getting out of additional countries. Does it answer your question?

It does. I mean the first part of the question was sort of the size of the customer bases in these countries that you're exiting?

Maybe I'll take...

Yeah. Go ahead Dana.

So in principle, we are really looking at a very, very long tail of a customer base. In these regions we've done very insignificant business. So this will -- does not have a substantial impact on our revenue growth or ARR growth as we -- as I alluded to in my part and we expect it to be almost not between 1.5 years.

Got it. Got it. And then, you mentioned AI as part of the enhancements that you're putting into your products. Can you give us a little bit more detail in terms of what that opportunity looks like longer term? And can that maybe change either the competitive sort of win rates or drive additional upsell opportunities. I just want to get a little bit more detail around that AI opportunity.

Yes, with pleasure, and really exciting in that context. First of all, we invest in AI as you probably remember and use it as part of the technological assets that we put into our investigative analytics Pathfinder and also in the PA. Look, we continue to invest here because we see AI capabilities, I would say on Physical Analyzer and Pathfinder is something that enable our customers to use it and quickly leverage insights which is by the way classic helpful for digital evidence and especially in investigative world. Because as we move forward with AI, we will see that it will play a bigger role and an important role. And you can think about it like that that in the investigative world, what we can help and offer is basically add with technology, improvement of mode of operation for the investigators around creating investigative scenarios and help with classifications of media, location, images, et cetera, et cetera. As a result, as you probably understand, that will be a differentiator, creates obviously increased business opportunities into the future. And especially in those two areas that I've mentioned, one Collect and Review with Physical Analyzer; and second the ongoing interest which is related to Pathfinder investigative analytics. So, definitely a technological benefit with an ongoing business opportunity for us.

Fantastic. Thank you.

And we'll take our next question from Shaul Eyal with TD Cowen.

Thank you. Good afternoon, Yossi, Dana, Andy, congrats, good to see the ongoing stability in the business, great progress also on the governance front. My first question Yossi is actually on the pipeline. How would you characterize the pipeline? Is it close to record levels? Also did most of the slippage from the past probably year, did that already come back?

I would say the following. First of all, it's a healthy market, Shaul. This is one. Second the pipeline is healthy, especially as we look forward even beyond Q2 to Q3 and Q4. And I would even say that in the perspective of 2023 and beyond, we feel very confident right now in something that I can say is scalable, can grow as we expected and relying among others on a very stable pipeline. When it comes to what we were facing in the past, I said all the time the market is healthy and we had to upgrade and correct some elements which are related to our go-to-market. We did in the USA, in EMEA and we feel I would say also very comfortable in the combination between the existing pipeline, the pipeline health and our ability to execute with our go-to-market organization.

Understood. Understood. Thank you for this color. And my second question. So, Magnet Forensics, as we all know, I was merged with Grayshift, Thoma Bravo pursued both these transactions. I know it could be early days you'll see, but have you witnessed any change within the competitive landscape?

No major change in the competitive landscape, specifically to Magnet and Grayshift as spoken last quarter. One, that merge anticipated actually right now practical happening merge is good for the market. It shows the attractiveness of the market. It was not a surprise for us. Those entities were as standalone collaborating with each other at the past. I also say that the merge reflects actually the value of Cellebrite because it was among others based on the importance of the mobile, as part of the entire scheme. Back to the question about the changes. So no changes not there and not in general. We continue to see smaller competitors from time to time that attempt to match elements of our product strategy. Our investment in innovation I would say, the strong customer relationship that we have and our ability to scale our position. We need to continue with our plan. And we believe that 2023 will be an important progress in that respect with our competition. We need to do our thing.

Understood. Thank you for that, congrats.

Thank you.

Next question operator.

And we'll take our next question from Tal Liani with Bank of America.

Hi. Good morning. Private sector, you mentioned new sales initiative and growth in the private sector. Can you give us a little bit more details first of all on your efforts to drive growth and opportunities et cetera?

So obviously look, private sector, I would say private sector revenue in Cellebrite's was and still slightly below the 10% of our total quarterly revenue. We believe that the current growth rate is substantially with good potential. And we have the ability to accelerate, based on the current offering that we have. Again, it's collection, its remote collection. And there is also some moves that we are doing in order to collaborate with additional partners within the industry. I would say that maybe a little bit about what drives deals over there on the deal-size. So in the public sector, by the way, similar to the in the private similar to the public deal size for the private sector customers is a function of products which are needed and the numbers of licenses. And even I would say larger corporate customers will generally require far less licenses for their IT and legal teams involved in conducting investigation. So, the largest enterprise are stuff similar to the forensic club or I would say by the small to midsized customer in the public. And as such, what I want to say with that, you will continue to see weak we'll continue to see the growth. It's not the pace of growth that we see in the public. But one we are satisfied with what we see. I also mentioned that we upgraded the sales team, sales leadership over there and we've got right now a team that can scale this up. It will stay around the 10% of our activity into the future as long as we operate organically. But it's good because the entire price grows and the pie of the private sector as part of our activity growth as well.

Got it. I have a second question with your permission. You talked about -- in the last two quarters you talked about deal slippage this quarter is very strong. Are you still seeing slippage of deals? And can you speak generally about how macroeconomic conditions are impacting projects and scrutiny of projects?

I'll start with the second part. We do not see any macroeconomic elements which are disturbing the business at the moment. I would say on the contrary we spoke in the past about fears from de-funding. Now the context is between funding to refunding of police. Slippery deals were mentioned last year and it was in the context of our ability to close and bring it to the end and timely manner especially by large deals which tends to be lumpy. I believe that, right now, I don't believe, I'm sure that right now if we look at it we're in a much better shape, maybe to emphasize the last statement the reasonable dependency in Cellebrite on that big large deal or that big project. We have a very good balance and it's very good for us in terms of business or risk management in business. There are increasing -- there is an increasing number of large deals. But those are not mega size deals which were independently on the entire quarter. And they improved side-by-side with our ability to continue growing with this transactional business by those thousands of long-tail prime customers in the state and local government. So, less lumpiness, diversified environment and small dependencies on mega large deals in order to meet the targets, we're in a good shape there.

Great. Thank you.

And we'll take our next question from Doug Bruehl with JPMorgan.

Hey good morning and thanks for taking my question. So looking at your ARR slide and seeing that growth over the past year really driven almost entirely by expansion of revenue. What products and services are you seeing the most strength in for that expansion component?

So maybe I'll take it Yossi. Predominantly from a volume and dollar perspective, the Collect and Review being our major installed base is driving most of the growth with further penetration of our advanced collection capabilities in the shape of premium solutions. We do see faster ARR growth with our investigative analytics and the Guardian solutions. But as they are coming from a smaller basis, the impact of the total dollar amount and the mix and the average ARR growth is marginal currently.

Great. That's all for me. Thank you.

Welcome.

And we'll take our next question from Jamie Shelton with Deutsche Bank.

Good morning and thanks for taking my question and congrats on the solid execution. It's great to see the launch of Pathfinder X. And you've touched on it briefly, but if you could talk to recent Pathfinder momentum as well as any additional color around contribution and growth today? And I guess, more importantly, where you think this could go over the next few years? And I've got a quick follow-up. Thank you.

Thank you for the question. Dana will take it maybe at least for a start. Look although Pathfinder has been available for several years, it is only with the past, I would say, two years that the product has achieved the level of functionality to gain traction within customers. And we've closed dozens of Pathfinder deals over the past year, as we I would say cross-sell and upsell, this offering in our installed base. And in Q1 by the way, we highlighted three customers bill that included Pathfinder. Pathfinder position Cellebrite very strongly in almost some kind of sole source offering when it comes to the investigative world. It is a BI which is dedicated to the way an investigator operates. It is also a great opportunity to take the -- especially in unique way data is being collected with our Collect and Review and then analyze that large amount of data in order to get to the evidence as quick as possible. Now it will -- we anticipate that it will boom in the future in a positive context a significant growth. It is involved selling that is involved with longer sales cycle. It is involved with changing sometimes the mode of operation of the customer. But as I look at it we continue to look at it as a significant growth opportunity for the investigative segment and definitely a relative advantage for us.

And just a quick follow-up. Can you provide us what percent of your UFED base is now connected to premium enterprise?

I'll take it. So I would say that we are -- it's the mid-teens in average of connected usage with senior enterprise.

Thank you. Understood.

Welcome.

[Operator Instructions] We'll take our next question from Louie DiPalma with William Blair.

Yossi, Dana, and Andy, good morning.

Good morning.

Good morning.

Following on my colleague Jonathan's question is there a potential for you to forge commercial partnerships with some of the generative AI vendors like open AI or Google to integrate those systems with your Physical Analyzer and perhaps like upsell that like AI capability to your current installed base?

Look, in general, collaborations are always possible, but one needs to remember that we are dealing with investigators and we are dealing with investigative data. And it is important for us also to, let's say, to keep the knowledge in out and make sure that we are giving something which is reliable closed contained and stable enough. The investment that we do in AI has been primarily focused on developing our machine learning models including those four, I would say, media and topic classification. And obviously we'll continue to explore ways that I would say open source-based AI models can complement our own capabilities and let's say further enhance and support the solution. So, yes, for the auction but we'll see into the future.

Great. That makes total sense. And another question. Many vendors in public safety have implemented price increases over the past year in this inflationary environment. Did you increase the pricing on any of your key products, or is there the potential for you to do so in the future to add to the existing core growth?

So first of all, yes, there is an option for an ongoing price increase. In addition, we actually just now increased the prices in the public sector for our Collect and Review and investigative analytics in the beginning of Q2. So the activity in Q1 didn't basically was not affected by that. The statement is by the way valid mainly for the US or the Americas because in the beginning of the year we did some modifications in the pricing to Europe based on the currency exchange -- currency rates. Into the future and since you are talking to a company which is facing its growth mainly on growing within the existing accounts, existing logos and focusing on strategic mid-high and the large federals, we intend or we think that we can see continuous price increasing for the value that we bring into our solutions. So it is also part of the strategy for the future to come. And to sum it up. So yes and yes.

Thanks, Yossi. Thanks everyone.

This concludes the Q&A portion of today's call. I would now like to turn the floor over to Cellebrite CEO, Yossi Carmil for additional or closing remarks.

Okay. So thank you again everyone for joining us. Thank you for the questions. And thank you, especially, for the Cellebrite employees for a great Q1 and good luck to us in the rest -- for the rest of the year. Thank you. Have a great day.

Thank you. This concludes today's Cellebrite first quarter 2023 financial results conference call. Please disconnect your line at this time and have a wonderful day.